Have a feature idea you'd love to see implemented?
Let us know!
JSPR Jasper Therapeutics Inc
Price (delayed)
$21.84
Market cap
$327.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.72
Enterprise value
$236.78M
Highlights
The EPS is up by 43% year-on-year and by 7% since the previous quarter
JSPR's debt is down by 31% YoY and by 11% QoQ
JSPR's quick ratio is down by 30% since the previous quarter and by 15% year-on-year
JSPR's equity is down by 17% since the previous quarter and by 11% year-on-year
Key stats
What are the main financial stats of JSPR
Market
Valuations
Earnings
Shares outstanding
15M
Market cap
$327.63M
Enterprise value
$236.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.94
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$63.53M
EBITDA
-$61.65M
Free cash flow
-$58.63M
Per share
Balance sheet
Liquidity
EPS
-$4.72
Free cash flow per share
-$3.91
Book value per share
$5.54
Revenue per share
$0
TBVPS
$6.63
Total assets
$99.41M
Total liabilities
$15.73M
Debt
$2.07M
Equity
$83.68M
Working capital
$82.35M
Debt to equity
0.02
Current ratio
7.61
Quick ratio
7.46
Net debt/EBITDA
1.47
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-58.5%
Return on equity
-67.6%
Return on invested capital
N/A
Return on capital employed
-73.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JSPR stock price
How has the Jasper Therapeutics stock price performed over time
Intraday
4.1%
1 week
-1.18%
1 month
9.75%
1 year
240.72%
YTD
176.81%
QTD
16.11%
Financial performance
How have Jasper Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$68.68M
Net income
-$63.53M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 6% year-on-year
Jasper Therapeutics's net income has decreased by 4% YoY
Growth
What is Jasper Therapeutics's growth rate over time
Valuation
What is Jasper Therapeutics stock price valuation
P/E
N/A
P/B
3.94
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 43% year-on-year and by 7% since the previous quarter
The price to book (P/B) is 39% lower than the 5-year quarterly average of 6.5 but 31% higher than the last 4 quarters average of 3.0
JSPR's equity is down by 17% since the previous quarter and by 11% year-on-year
Efficiency
How efficient is Jasper Therapeutics business performance
The company's return on assets fell by 4.3% QoQ
The company's return on equity fell by 4.5% QoQ
Dividends
What is JSPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JSPR.
Financial health
How did Jasper Therapeutics financials performed over time
JSPR's quick ratio is down by 30% since the previous quarter and by 15% year-on-year
The current ratio has decreased by 29% from the previous quarter and by 14% YoY
JSPR's debt is 98% lower than its equity
The debt to equity has declined by 33% year-on-year
JSPR's debt is down by 31% YoY and by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.